Targeted DNA demethylation in vivo using dCas9–peptide repeat and scFv–TET1 catalytic domain fusions is a research paper published in Nature Biotechnology (2016). On theSindex it has a DataRank of 10.5. It has been cited 513 times, with 200 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.936
From this paper's citation signal
Citation Network Contribution
9.6
From 200 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 200 citers.
FWCI
27.42
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 2 of Successful generation of epigenetic disease model mice by targeted demethylation of the epigenome
Additional file 2 of Successful generation of epigenetic disease model mice by targeted demethylation of the epigenome
Additional file 3 of Successful generation of epigenetic disease model mice by targeted demethylation of the epigenome
Additional file 3 of Successful generation of epigenetic disease model mice by targeted demethylation of the epigenome
Additional file 1 of Efficient generation of epigenetic disease model mice by epigenome editing using the piggyBac transposon system
Additional file 1 of Efficient generation of epigenetic disease model mice by epigenome editing using the piggyBac transposon system
Additional file 12 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
Additional file 12 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
Additional file 13 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
Additional file 13 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
Additional file 14 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
Additional file 14 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
Additional file 1 of Functional characterization of age-dependent p16 epimutation reveals biological drivers and therapeutic targets for colorectal cancer
Additional file 1 of Functional characterization of age-dependent p16 epimutation reveals biological drivers and therapeutic targets for colorectal cancer
Additional file 2 of Functional characterization of age-dependent p16 epimutation reveals biological drivers and therapeutic targets for colorectal cancer
Additional file 2 of Functional characterization of age-dependent p16 epimutation reveals biological drivers and therapeutic targets for colorectal cancer
Additional file 1 of Targeted demethylation of the SLC5A7 promotor inhibits colorectal cancer progression
Additional file 2 of Targeted demethylation of the SLC5A7 promotor inhibits colorectal cancer progression
Additional file 1 of Targeted demethylation of the SLC5A7 promotor inhibits colorectal cancer progression
Additional file 2 of Targeted demethylation of the SLC5A7 promotor inhibits colorectal cancer progression